FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997341767> ?p ?o ?g. }

• W1997341767 endingPage "1490" @default.
• W1997341767 startingPage "1483" @default.
• W1997341767 abstract "Management of secondary hyperparathyroidism has included the use of active vitamin D or vitamin D analogs for the suppression of parathyroid hormone (PTH) secretion. Although, these agents are effective, therapy is frequently limited by hypercalcemia, hyperphosphatemia, and/or elevations in the calcium-phosphorus (Ca x P) product. In clinical studies, paricalcitol was shown to be effective at reducing PTH concentrations without causing significant hypercalcemia or hyperphosphatemia as compared to placebo. A comparative study was undertaken in order to determine whether paricalcitol provides a therapeutic advantage to calcitriol.A double-blind, randomized, multicenter study comparing the safety and effectiveness of intravenous paricalcitol and calcitriol in suppressing PTH concentrations in hemodialysis patients was performed. A total of 263 randomized patients were enrolled at domestic and international sites. Following the baseline period, patients with serum Ca x P < 75, and a PTH level > or =300 pg/mL were randomly assigned to receive either paricalcitol or calcitriol in a dose-escalating fashion for up to 32 weeks. Dose adjustments were based on laboratory results for PTH, calcium, and Ca x P. The primary end point was the greater than 50% reduction in baseline PTH. Secondary end points were the occurrence of hypercalcemia and elevated Ca x P product.Paricalcitol-treated patients achieved a > or =50% reduction from baseline PTH significantly faster than did the calcitriol-treated patients (P = 0.025) and achieved a mean reduction of PTH into a desired therapeutic range (100 to 300 pg/mL) at approximately week 18, whereas the calcitriol-treated patients, as a group, were unable to achieve this range. Moreover, paricalcitol-treated patients had significantly fewer sustained episodes of hypercalcemia and/or increased Ca x P product than calcitriol patients (P = 0.008).Paricalcitol treatment reduced PTH concentrations more rapidly with fewer sustained episodes of hypercalcemia and increased Ca x P product than calcitriol therapy." @default.
• W1997341767 created "2016-06-24" @default.
• W1997341767 creator A5006630740 @default.
• W1997341767 creator A5025563502 @default.
• W1997341767 creator A5030580194 @default.
• W1997341767 creator A5040430472 @default.
• W1997341767 creator A5051229288 @default.
• W1997341767 date "2003-04-01" @default.
• W1997341767 modified "2023-09-30" @default.
• W1997341767 title "Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism" @default.
• W1997341767 cites W1958413320 @default.
• W1997341767 cites W1970659430 @default.
• W1997341767 cites W1973164863 @default.
• W1997341767 cites W1973775872 @default.
• W1997341767 cites W1989640819 @default.
• W1997341767 cites W1990329250 @default.
• W1997341767 cites W1994057975 @default.
• W1997341767 cites W2001480762 @default.
• W1997341767 cites W2011922602 @default.
• W1997341767 cites W2018429484 @default.
• W1997341767 cites W2024635160 @default.
• W1997341767 cites W2025339363 @default.
• W1997341767 cites W2030174339 @default.
• W1997341767 cites W2035440905 @default.
• W1997341767 cites W2038986027 @default.
• W1997341767 cites W2041692221 @default.
• W1997341767 cites W2044727825 @default.
• W1997341767 cites W2044977512 @default.
• W1997341767 cites W2050378937 @default.
• W1997341767 cites W2055923382 @default.
• W1997341767 cites W2082708611 @default.
• W1997341767 cites W2094803889 @default.
• W1997341767 cites W2095931056 @default.
• W1997341767 cites W2097889785 @default.
• W1997341767 cites W2113219485 @default.
• W1997341767 cites W2116527847 @default.
• W1997341767 cites W2235064564 @default.
• W1997341767 cites W2328615536 @default.
• W1997341767 cites W4252361825 @default.
• W1997341767 doi "https://doi.org/10.1046/j.1523-1755.2003.00878.x" @default.
• W1997341767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12631365" @default.
• W1997341767 hasPublicationYear "2003" @default.
• W1997341767 type Work @default.
• W1997341767 sameAs 1997341767 @default.
• W1997341767 citedByCount "348" @default.
• W1997341767 countsByYear W19973417672012 @default.
• W1997341767 countsByYear W19973417672013 @default.
• W1997341767 countsByYear W19973417672014 @default.
• W1997341767 countsByYear W19973417672015 @default.
• W1997341767 countsByYear W19973417672016 @default.
• W1997341767 countsByYear W19973417672017 @default.
• W1997341767 countsByYear W19973417672018 @default.
• W1997341767 countsByYear W19973417672019 @default.
• W1997341767 countsByYear W19973417672020 @default.
• W1997341767 countsByYear W19973417672021 @default.
• W1997341767 countsByYear W19973417672022 @default.
• W1997341767 countsByYear W19973417672023 @default.
• W1997341767 crossrefType "journal-article" @default.
• W1997341767 hasAuthorship W1997341767A5006630740 @default.
• W1997341767 hasAuthorship W1997341767A5025563502 @default.
• W1997341767 hasAuthorship W1997341767A5030580194 @default.
• W1997341767 hasAuthorship W1997341767A5040430472 @default.
• W1997341767 hasAuthorship W1997341767A5051229288 @default.
• W1997341767 hasBestOaLocation W19973417671 @default.
• W1997341767 hasConcept C124490489 @default.
• W1997341767 hasConcept C126322002 @default.
• W1997341767 hasConcept C126894567 @default.
• W1997341767 hasConcept C134018914 @default.
• W1997341767 hasConcept C142724271 @default.
• W1997341767 hasConcept C204787440 @default.
• W1997341767 hasConcept C27081682 @default.
• W1997341767 hasConcept C2775945674 @default.
• W1997341767 hasConcept C2776036575 @default.
• W1997341767 hasConcept C2776079296 @default.
• W1997341767 hasConcept C2778838027 @default.
• W1997341767 hasConcept C2779524405 @default.
• W1997341767 hasConcept C2781208988 @default.
• W1997341767 hasConcept C519063684 @default.
• W1997341767 hasConcept C71924100 @default.
• W1997341767 hasConceptScore W1997341767C124490489 @default.
• W1997341767 hasConceptScore W1997341767C126322002 @default.
• W1997341767 hasConceptScore W1997341767C126894567 @default.
• W1997341767 hasConceptScore W1997341767C134018914 @default.
• W1997341767 hasConceptScore W1997341767C142724271 @default.
• W1997341767 hasConceptScore W1997341767C204787440 @default.
• W1997341767 hasConceptScore W1997341767C27081682 @default.
• W1997341767 hasConceptScore W1997341767C2775945674 @default.
• W1997341767 hasConceptScore W1997341767C2776036575 @default.
• W1997341767 hasConceptScore W1997341767C2776079296 @default.
• W1997341767 hasConceptScore W1997341767C2778838027 @default.
• W1997341767 hasConceptScore W1997341767C2779524405 @default.
• W1997341767 hasConceptScore W1997341767C2781208988 @default.
• W1997341767 hasConceptScore W1997341767C519063684 @default.
• W1997341767 hasConceptScore W1997341767C71924100 @default.
• W1997341767 hasIssue "4" @default.
• W1997341767 hasLocation W19973417671 @default.
• W1997341767 hasLocation W19973417672 @default.
• W1997341767 hasOpenAccess W1997341767 @default.

• next